Clinicians treating adults with obesity or adults with overweight with at least one weight‑related condition should be aware that ZEPBOUND is an FDA‑approved pharmacotherapy option to reduce and maintain weight when added to a reduced‑calorie diet and increased physical activity ^[1][2]. The approval and trial data support mean body‑weight reductions of up to 18% at the highest approved dose versus placebo and label dosing that starts at 2.5 mg weekly with maintenance options of 5 mg, 10 mg, or 15 mg once weekly ^[2][1]. Do the weight reductions achieved with tirzepatide translate into reductions in cardiovascular events and long‑term clinical outcomes in broad practice populations?

Q1 What is ZEPBOUND (tirzepatide) approved for?

ZEPBOUND (tirzepatide) is approved to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight‑related comorbid condition, to be used in combination with a reduced‑calorie diet and increased physical activity. ZEPBOUND is also approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, in combination with a reduced‑calorie diet and increased physical activity.

Q2 How does tirzepatide work?

Tirzepatide is a dual glucose‑dependent insulinotropic polypeptide (GIP) receptor and glucagon‑like peptide‑1 (GLP‑1) receptor agonist that activates receptors of hormones secreted from the intestine to reduce appetite and food intake; the mechanism described in FDA materials attributes weight reduction to these receptor effects and resultant decreases in energy intake. The prescribing information and FDA press materials describe this dual agonist activity as the pharmacologic basis for both glycemic and weight effects.

Q3 What is the recommended dosing for ZEPBOUND?

The FDA‑approved dosing begins with a starting dosage of 2.5 mg injected subcutaneously once weekly for 4 weeks, with escalation in 2.5 mg increments after at least 4 weeks until the selected maintenance dosage is achieved; the recommended maintenance dosages for weight reduction are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly, and for OSA the recommended maintenance dosages are 10 mg or 15 mg once weekly. The maximum recommended dosage for all indications is 15 mg once weekly.

Q4 What are the most common side effects and safety considerations?

The most common adverse reactions reported in ≥5% of patients treated with ZEPBOUND included nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. ZEPBOUND carries a boxed warning for risk of thyroid C‑cell tumors observed in rats and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with MEN 2; other labeled warnings include severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, pancreatitis, hypersensitivity reactions, hypoglycemia with concomitant insulin or insulin secretagogue use, diabetic retinopathy complications monitoring, suicidal behavior and ideation, and pulmonary aspiration during anesthesia or deep sedation.